Inovio assumed with an Overweight at Piper Jaffray. Piper Jaffray analyst Christopher Raymond assumed coverage of Inovio Pharmaceuticals with an Overweight rating and $12 price target. The stock is “poised for upside” as investors are assigning little value to key programs like VGX-3100, in Phase 3 for the treatment of cervical dysplasia, and INO-5410, in Phase 1/2 for bladder cancer, Raymond tells investors in a research note. He views Inovio’s immunotherapy platform as differentiated with a number of key proof of concept data points in coming quarters. The analyst would be a buyer of the stock to levels approaching $12.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.